{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:07:09Z","timestamp":1788865629504,"version":"build-2803163510"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Stage III non-small cell lung cancer (NSCLC) is a highly heterogeneous disease, and recent phase III trials have demonstrated the efficacy of neoadjuvant and perioperative chemoimmunotherapy in selected patients. However, translating these data into consistent real-world multidisciplinary decision-making remains challenging because anatomical resectability, nodal burden, tumor biology, and treatment response vary substantially. Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival (EFS), with a modest but clinically meaningful overall survival (OS) benefit at five years. Perioperative strategies appear to extend these benefits: KEYNOTE-671 demonstrated a significant OS advantage, while AEGEAN and CheckMate 77T showed consistent EFS improvements, with OS data still maturing. However, cross-trial comparisons are inherently limited, and the incremental contribution of the adjuvant immunotherapy phase remains unclear. Exploratory subgroup analyses suggest potentially greater benefit in N2 disease, although prospective validation is required. For tumors harboring actionable oncogenic alterations, upfront resection followed by adjuvant targeted therapy remains the preferred strategy, whereas definitive chemoradiotherapy followed by consolidation durvalumab remains standard of care for unresectable stage III disease. Management of stage III NSCLC should be individualized through multidisciplinary assessment. Major uncertainties persist regarding the comparative efficacy of perioperative versus neoadjuvant-only strategies, the contribution of adjuvant immunotherapy, and the role of biomarker-guided treatment adaptation. This clinical framework provides structured guidance to support treatment selection across the heterogeneous spectrum of stage III disease, while recognizing that prospective validation of risk-adapted strategies remains essential.<\/jats:p>","DOI":"10.3389\/fonc.2026.1897546","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:12:50Z","timestamp":1788862370000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk-adaptive management of stage III NSCLC in the perioperative immunotherapy era: a critical synthesis and clinical framework"],"prefix":"10.3389","volume":"16","author":[{"given":"\u0130brahim","family":"Y\u0131ld\u0131z","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Ac\u0131badem Mehmet Ali Ayd\u0131nlar University","place":["\u0130stanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"\u015eenocak Ta\u015f\u00e7\u0131","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Ac\u0131badem Mehmet Ali Ayd\u0131nlar University","place":["\u0130stanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulya","family":"A\u011fao\u011flu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, School of Medicine, Ac\u0131badem Mehmet Ali Ayd\u0131nlar University","place":["\u0130stanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv187","article-title":"2nd ESMO Consensus Conference in lung cancer: locally advanced stage III non-small-cell lung cancer","volume":"26","author":"Eberhardt","year":"2015","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.003","article-title":"Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Zer","year":"2025","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.chest.2016.10.010","article-title":"The eighth edition lung cancer stage classification","volume":"151","author":"Detterbeck","year":"2017","journal-title":"Chest"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.10.012","article-title":"The International Association for the Study of Lung Cancer Staging Project for lung cancer: proposals for the revision of the N descriptors in the forthcoming ninth edition of the TNM classification for lung cancer","volume":"19","author":"Huang","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.0057","article-title":"Neoadjuvant chemoimmunotherapy for NSCLC: a systematic review and meta-analysis","volume":"10","author":"Sorin","year":"2024","journal-title":"JAMA Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1286104","article-title":"Neoadjuvant therapy in non-small cell lung cancer: basis, promise, and challenges","volume":"13","author":"Kalvapudi","year":"2023","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2355","article-title":"Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"143","author":"Silvestri","year":"2013","journal-title":"Chest"},{"key":"B14","doi-asserted-by":"publisher","first-page":"230191","DOI":"10.1183\/20734735.0191-2023","article-title":"Mediastinal staging of nonsmall cell lung cancer: what's new","volume":"21","author":"Bradley","year":"2025","journal-title":"Breathe (Sheff)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezu028","article-title":"Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer","volume":"45","author":"De Leyn","year":"2014","journal-title":"Eur J Cardiothorac Surg"},{"key":"B16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12880-021-00580-w","article-title":"Impact of 18F-FDG PET\/CT, CT and EBUS\/TBNA on preoperative mediastinal nodal staging of NSCLC","volume":"21","author":"Al-Ibraheem","year":"2021","journal-title":"BMC Med Imaging"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/cells14130971","article-title":"Perioperative management of non-small cell lung cancer in the era of immunotherapy","volume":"14","author":"Kumbasar","year":"2025","journal-title":"Cells"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2502931","article-title":"Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer","volume":"393","author":"Forde","year":"2025","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105759","article-title":"Immunotherapy for resectable NSCLC: neoadjuvant\/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses","volume":"10","author":"Rossi","year":"2025","journal-title":"ESMO Open"},{"key":"B23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13643-025-02767-6","article-title":"Perioperative or neo\/adjuvant chemoimmunotherapy versus chemotherapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis","volume":"14","author":"Zhang","year":"2025","journal-title":"Syst Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O'Brien","year":"2022","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.079","article-title":"Perioperative pembrolizumab in early-stage non-small-cell lung cancer (NSCLC): 5-year follow-up from KEYNOTE-671","volume":"36","author":"Wakelee","year":"2025","journal-title":"Ann Oncol."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-01104-z","article-title":"Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis","volume":"7","author":"Provencio","year":"2026","journal-title":"Nat Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.069","article-title":"Perioperative durvalumab for resectable NSCLC (R-NSCLC): updated outcomes from the phase 3 AEGEAN trial","volume":"19","author":"Heymach","year":"2024","journal-title":"J Thorac Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"LBA8010","DOI":"10.1200\/jco.2025.43.17_suppl.lba8010","article-title":"Perioperative nivolumab (NIVO) vs placebo (PBO) in patients (pts) with resectable NSCLC: updated survival and biomarker analyses from CheckMate 77T","volume":"43","author":"Cascone","year":"2025","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the NEOTORCH randomized clinical trial","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-1213","article-title":"Perioperative dynamic changes in circulating tumor DNA in patients with lung cancer (DYNAMIC)","volume":"25","author":"Chen","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.561598","article-title":"Circulating tumor DNA as a prognostic biomarker in localized non-small-cell lung cancer","volume":"10","author":"Peng","year":"2020","journal-title":"Front Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41698-025-00984-9","article-title":"A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer","volume":"9","author":"Boukouris","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/srep34388","article-title":"Neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for resectable stage III non-small-cell lung cancer: a meta-analysis","volume":"6","author":"Guo","year":"2016","journal-title":"Sci Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(08)70156-6","article-title":"Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer","volume":"9","author":"Thomas","year":"2008","journal-title":"Lancet Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)60294-x","article-title":"Induction chemoradiation in stage IIIA\/N2 non-small-cell lung cancer: a phase 3 randomised trial","volume":"386","author":"Pless","year":"2015","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.athoracsur.2024.09.041","article-title":"The Society of Thoracic Surgeons expert consensus on the multidisciplinary management and resectability of locally advanced non-small cell lung cancer","volume":"119","author":"Kim","year":"2025","journal-title":"Ann Thorac Surg"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02528","article-title":"Management of stage III non-small-cell lung cancer: ASCO guideline","volume":"40","author":"Daly","year":"2022","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(09)60737-6","article-title":"Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial","volume":"374","author":"Albain","year":"2009","journal-title":"Lancet"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.10.003","article-title":"Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study","volume":"18","author":"Girard","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00036","article-title":"Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non-small cell lung cancer: the phase III PACIFIC-2 study","volume":"43","author":"Bradley","year":"2025","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194782","article-title":"Parenchymal sparing surgery for lung cancer: focus on pulmonary artery reconstruction","volume":"14","author":"Menna","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2024.10.007","article-title":"Outcomes after neoadjuvant therapy with or without immunotherapy followed by pneumonectomy in non-small cell lung cancer patients","volume":"120","author":"Li","year":"2025","journal-title":"Ann Thorac Surg"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091426","article-title":"Surgical outcomes after neoadjuvant chemo-immunotherapy for stage III NSCLC: a systematic review and meta-analysis","volume":"17","author":"Bardoni","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00432-024-05683-9","article-title":"Development of postoperative bronchopleural fistula after neoadjuvant immunochemotherapy in non-small cell lung cancer: case reports and review of the literature","volume":"150","author":"Zhao","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.06.010","article-title":"Neoadjuvant and adjuvant treatments for early-stage resectable NSCLC: consensus recommendations from the International Association for the Study of Lung Cancer","volume":"19","author":"Spicer","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00883","article-title":"Neoadjuvant osimertinib for resectable EGFR-mutated non-small cell lung cancer","volume":"43","author":"He","year":"2025","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.8015","article-title":"Alectinib as neoadjuvant treatment in potentially resectable stage III ALK-positive NSCLC: final analysis of ALNEO phase II trial (GOIRC-01-2020-ML42316)","volume":"43","author":"Leonetti","year":"2025","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B56","unstructured":"NCCN Clinical Practice Guidelines in Oncology: non-Small Cell Lung Cancer. Version 1.2026\n          \n          \n          \n          2026"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1897546\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:12:52Z","timestamp":1788862372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1897546\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":56,"alternative-id":["10.3389\/fonc.2026.1897546"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1897546","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1897546"}}